+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol

Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol

Archives of Gynecology and Obstetrics 261(4): 201-208

Background: The ideal progestin for combined hormone replacement therapy should be free of adverse effects on lipid metabolism. We therefore examined lipid profiles during continuous hormone replacement therapy (HRT) with an estradiol-gel combined with either a levonorgestrel-releasing intrauterine device (LNG-IUD) or oral/vaginal natural progesterone. Methods: Sixty menopausal women recruited in this open, non-randomised parallel three-group study received percutaneous gel containing 1.5 mg of estradiol daily. Progestin was administered to the women with an LNG-IUD (n = 20), as oral natural progesterone (n=21) 100 mg daily on the 1 - 25 calendar days of the month or as vaginal progesterone (n = 19) 100 - 200 mg daily on the 1 - 25 calendar days of the month. Serum concentrations for total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and sex hormone binding globulin (SHBG) were measured at 0, 6 and 12 months. The median (and 95% confidence interval) of the serum SHBG, total, LDL-, HDL-cholesterol and triglycerides concentrations at baseline and after 6 and 12 months of the study and the ratio of 6 and 12 months values to baseline values were calculated. Results: Total cholesterol was significantly decreased (8%) in the vaginal progesterone group at the end of the trial. HDL-cholesterol did not change in either of the progesterone groups, while a slight but transient decrease (median 15%) was seen at 6 months in the LNG-IUD group. There were no significant changes in triglycerides or LDL-cholesterol concentrations in any group. SHBG did not change significantly in the LNG-IUD and vaginal progesterone groups, while a slight but transient increase was seen in oral P group at 6 months. Conclusions: As the only significant harmful effect observed was a transient decrease in HDL-cholesterol in the LNG-IUD group at 6 months, each of these HRT-administration methods can be regarded as being safe in their effects on lipid metabolism.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 008959529

Download citation: RISBibTeXText

PMID: 9789651

DOI: 10.1007/s004040050222

Related references

Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 26(3): 211-217, 1997

Endometrial response in post menopausal women during treatment with percutaneous 17 beta estradiol opposed by oral progesterone. Maturitas 8(3): 201-208, 1986

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: Clinical and endometrial responses. Maturitas 26(2): 103-111, 1997

Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment. International Journal of Fertility and Menopausal Studies 41(5): 476-483, 1996

Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstetricia Et Gynecologica Scandinavica. 77(7): 758-763,., 1998

Oral vs. vaginal absorption of estradiol in post menopausal women effects of different particle sizes. Upsala Journal of Medical Sciences 86(3): 297-308, 1981

Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecologic Oncology 146(1): 34-38, 2017

Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertility and Sterility 83(2): 398-404, 2005

High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scandinavian Journal of Clinical and Laboratory Investigation 67(3): 257-263, 2007

Clinical and endometrial effects of estradiol and progesterone and post menopausal women. Maturitas 13(2): 109-116, 1991

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. Menopause 2019, 2019

Hormone replacement therapy with transdermal estradiol gel and oral progesterone: Effects on menopausal symptoms and lipid metabolism. Wiener Klinische Wochenschrift 112(14): 629-633, 28 Juli, 2000

One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. Experimental and Clinical Endocrinology and Diabetes 111(5): 267-273, 2003

Pharmaco kinetics and pharmacodynamic effects of vaginal estradiol administration from silastic rings in post menopausal women. Maturitas 3(2): 125-134, 1981

Effects of hormone therapy on the endometrium in postmenopausal women: a one year randomized trial of low dose oral estradiol in association with a levonorgestrel-releasing intrauterine system or drospirenone. Revista Brasileira de Saúde Materno Infantil 13(3): 259-266, 2013